At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Comparison of Tailored Antiplatelet Therapy With Early Escalation and Late De-Escalation Strategy Versus Standard Dual Antiplatelet Therapy in Patients Undergoing Complex High-Risk Percutaneous Coronary Intervention
In Brief
A Phase 4 clinical trial evaluating Tailored antithrombotic strategy and Conventional antithrombotic strategy for Coronary Stenoses. Completed, enrolled 2,018 participants across 22 sites.
Detailed Summary
This study evaluates the efficacy and safety of tailored antithrombotic therapy with early (\<6-month post-PCI) intensified (low-dose ticagrelor \[120 mg loading, then 60 mg bid maintenance\] and aspirin) and late (\>6-month post-PCI) deescalated (clopidogrel alone) strategy in patients undergoing high-risk complex PCI as compared with standard Dual Antiplatelet Therapy(aspirin and clopidogrel for 12 months).
Study Details
Timeline
Interventions
Low-dose (60mg) ticagrelor + aspirin for 6months and then clopidogrel alone for 6months
Clopidogrel + aspirin for 12months